Inhibitor Therapeutics, Inc. (INTI)

OTCMKTS · Delayed Price · Currency is USD

0.0450

-0.0038 (-7.71%)

At close: Dec 19, 2025

-39.38% (1Y)

Market Cap	7.77M
Revenue (ttm)	n/a
Net Income (ttm)	-3.43M
Shares Out	172.57M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,280
Average Volume	24,851
Open	0.0450
Previous Close	0.0488
Day's Range	0.0450 - 0.0450
52-Week Range	0.0338 - 0.0784
Beta	-0.52
RSI	51.02
Earnings Date	Mar 27, 2026

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1992

Employees 9

Stock Exchange OTCMKTS

Ticker Symbol INTI

Full Company Profile

Financial Performance

Financial Statements

News

Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024

Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Complement Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.

1 year ago - GlobeNewsWire

Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight

The complement inhibitors market is gaining momentum due to the rising recognition of the complement system's role in driving rare and chronic diseases, such as paroxysmal nocturnal hemoglobinuria (PN...